Diagnosis and treatment of Parkinson disease: molecules to medicine.

By J. Savitt, Valina L. Dawson, T. Dawson. Journal of Clinical Investigation, 2006

644 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/023dab243f57828da60bae0c93b7b0fd2f2af27f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. H. Ko
2. Valina L. Dawson
3. T. Dawson

In Neurology

1. H. Ko
2. Valina L. Dawson
3. T. Dawson
4. Mark P. Mattson
5. D. Selkoe

Citations in the corpus

• PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson’s Disease (2011, neutral): “Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized phenotypically by bradykinesia, rigidity, tremor, and neuropsychiatric disturbances (Savitt et al., 2006).”
• PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 (2010, neutral): “dtd" [ ]> Parkinson's disease is the most common movement disorder and results from selective and massive loss of dopamine-containing neurons in the Substantia Nigra pars compacta (SNpc”
• Genetic Animal Models of Parkinson’s Disease (2010, positive): “Therefore, it is essential to develop suitable animal models that can be used for the screening and testing of new therapeutic strategies targeting the actual pathogenic process as opposed to merely developing symptomatic therapies (Savitt et al., 2006).”